Clinical Trials Logo

Clinical Trial Summary

The study aims to examine the effect of probiotics on the clinical symptoms of allergic rhinitis and to elucidate some of the immunological mechanisms involved.


Clinical Trial Description

Epidemiological studies have shown that the incidence of atopic diseases (eczema, food allergy, allergic rhinitis and asthma) has been rising over the last few decades. The rate of increase precludes genetic make-up as the sole cause of the atopic epidemic and implicates environmental factors instead. Currently, allergic rhinitis (hay fever) is one of the world's most common chronic allergic diseases. It affects over 600 million people and often leads to asthma. There are huge costs associated with the condition in terms of both health care and work days lost, with British businesses estimated to lose £324 million this summer alone. For the sufferers, the symptoms severely affect their quality of life. It disturbs their sleep and impairs daytime concentration and performance at work or school. Currently there is no cure for it.

The importance of the gut microbiota in general well-being is evidenced by several experimental observations. It is difficult to achieve oral tolerance in germ-free animals [Sudo et al. 1997] while administration of lipopolysaccharide (a constituent of the outer membrane of gram-negative bacteria) together with food antigens increases the tolerizing effect of feeding [Kim & Ohsawa 1995]. While able to assist in tolerance induction, bacterial products may also break oral tolerance [Gaboriau-Routhiau et al. 1996]. These findings led Wold to suggest in 1998 that an altered normal intestinal colonization pattern in infancy, which fails to induce immunological tolerance, could be responsible for the increase in allergies. Recent studies suggest that the effects of the gut microbiota may not only be related to food antigens, but also to aeroallergens [Noverr et al. 2004, 2005]. Forsythe and his colleagues (2007) managed to attenuate adverse airway responses in a mouse model of allergic asthma through oral administration of probiotics.

The mechanisms by which probiotics exert their effects are unknown at present, but experiments in mice have documented improved gastrointestinal barrier function [Ewaschuk et al. 2008]. Since these experiments have also revealed a strain-dependent heterogeneity in the efficacy of probiotics [N.G. Hord 2008] it is unlikely that improved barrier function alone is responsible for the beneficial effects noted. Given the sheer numbers of microorganisms that inhabit our mucosal surfaces, it is likely that there are normally bidirectional interactions between them and the epithelial, immune, neurologic and endocrine physiological processes initiated by and between them. We hypothesize that a probiotic organism is ingested in sufficient quantities to amplify its particular trait relative to the milieu of other organisms present in relatively lower quantities, temporarily over-riding the diversity present. In that case, the transfer of information between the probiotic organism and cellular components of the gut has particular impact. In order to understand and manipulate this probiotic-mucosa cross-talk towards therapeutic advantage, there is a need to focus on the transfer of information between the microbiota and cellular components of the mucosal immune system.

Few studies have examined the effect of probiotics on allergic rhinitis and the studies that have been performed [Helin et al. 2002; Wang et al. 2004; Xiao et al. 2006] are inconclusive. In our own pilot study we tested the ability of Lactobacillus casei Shirota (LcS) to alter immunological events in seasonal allergic rhinitis (SAR) [Ivory et al. 2008]. The study format was double-blinded and placebo-controlled with ten SAR sufferers in each group. We compared changes in immune status arising through the daily ingestion of a milk drink supplied by Yakult, with or without live LcS, over a period of 5 months. Pre-, peak- and post-grass pollen season blood samples were collected for determination of plasma grass pollen-specific IgG and IgE levels by immunoassay. At the same time, cytokine levels were determined by flow cytometric bead array technology following culture of peripheral blood mononuclear cells for six days in the presence or absence of specific grass pollen antigens. We found that volunteers treated with LcS showed a significant reduction in levels of antigen-induced IL-5, IL-6 and IFN- production compared to volunteers supplemented with placebo. Meanwhile, levels of pollen-specific IgG increased and IgE decreased in the probiotic group. Other changes in cytokine levels were seen but they did not attain statistical significance, most likely due to the small number of volunteers tested. Our work has established for the first time that probiotic supplementation modulates immune responses in allergic rhinitis through down-regulation of both Th1- and Th2-type cytokines and to beneficially alter the balance of pollen-specific IgG and IgE levels in allergic rhinitis subjects. It has also suggested that the impact of probiotics reaches beyond the intestine.

We would now like to conduct another study to show that the immunological changes arising through probiotic consumption have an impact on the clinical symptoms of hay fever. In addition, we propose to elucidate some of the mechanisms involved that may contribute to the health benefit. As far as we know there have not been any similar studies to date. The ability to demonstrate clinical efficacy of dietary intervention for hay fever treatment has obvious benefits for the relevant sufferers. Economic benefits would arise through the relatively inexpensive 'treatment' that would be self-administered and likely lower absenteeism from work. There is also a need for evidence-based viability for the many health claims made for probiotic consumption that could result in clear guidance to the general public. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care


Related Conditions & MeSH terms


NCT number NCT01123252
Study type Interventional
Source University of East Anglia
Contact
Status Completed
Phase Phase 2
Start date September 2010
Completion date April 2011

See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device